Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antibody Structure

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...

Transcytosis of IgG

Transcytosis of IgG

Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Biochemical and haemostatic variables associated with metastasis in dogs with carcinoma or sarcoma.

The Journal of small animal practice·2025

Same author

[Association between estimated cumulative LDL-C exposure and coronary artery disease severity and 2-year prognosis in acute coronary syndrome patients].

Zhonghua xin xue guan bing za zhi·2025

Same author

[Research progress of proximity extension assay in coronary heart disease].

Zhonghua xin xue guan bing za zhi·2025

Same author

[Effect of LDL-C/HDL-C ratio on severity of coronary artery disease and 2-year long-term prognosis in elderly patients with coronary heart disease].

Zhonghua yi xue za zhi·2024

Same author

Volatile capture technology in sustainable anaesthetic practice: a narrative review.

Anaesthesia·2024

Same author

[The connotation of universal health management and its implementation in the context of Healthy China Strategy].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2023

Search research articles

Related Experiment Video

Updated: Jul 10, 2026

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

An efficient route to human bispecific IgG

A M Merchant¹, Z Zhu, J Q Yuan

¹Department of Molecular Oncology, Genentech Inc., South San Francisco, CA 94080, USA.

Nature Biotechnology

|July 14, 1998

Summary

Engineered bispecific IgG (BsIgG) production overcomes inefficient chain pairing using novel heavy chain modifications and identical light chains. This approach enables high-yield BsIgG with retained effector functions for targeted therapies.

More Related Videos

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Related Experiment Videos

Last Updated: Jul 10, 2026

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Area of Science:

Biotechnology
Immunology
Protein Engineering

Background:

Bispecific IgG (BsIgG) production is inefficient due to random heavy and light chain pairing.
Unwanted antibody chain combinations reduce yield and purity of desired BsIgG molecules.

Purpose of the Study:

To engineer efficient heterodimerization of antibody heavy chains for BsIgG production.
To circumvent light chain mispairing by utilizing a common light chain for BsIgG.

Main Methods:

Engineered disulfide bonds and "knobs-into-holes" mutations were introduced into antibody heavy chains to promote heterodimerization.
A common light chain was employed for both arms of the BsIgG to prevent light chain mispairing.
Antibodies with common light chains binding to different antigens were selected using an scFv phage library.

Main Results:

A specific heavy chain variant achieved approximately 95% heterodimerization efficiency.
The common light chain strategy successfully prevented light chain mispairing.
A BsIgG targeting HER3 and cMpI was successfully produced and purified using protein A chromatography.
Engineered heavy chains maintained antibody-dependent cell-mediated cytotoxicity (ADCC) activity.

Conclusions:

The developed heavy chain engineering strategy significantly enhances BsIgG heterodimerization efficiency.
Utilizing a common light chain is an effective method to avoid mispairing in BsIgG production.
This engineered BsIgG platform retains effector functions and enables simultaneous targeting of multiple receptors.